Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination

Blood Pressure

Volumn 17, Issue SUPPL. 2, 2008, Pages 13-21

  Trenkwalder, P ^a   Schaetzl, R ^b   Borbas, E ^c   Handrock, R ^d   Klebs, S ^d  

^a Starnberg Hospital   (Germany)

^b Practice for General Medicine   (Germany)

^c Internal Medicine   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Amlodipine; Angiotensin receptor blockers; Calcium channel blockers; Combination therapy; Hypertension; Valsartan

Indexed keywords

AMLODIPINE; FELODIPINE; RAMIPRIL; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FALLING; FEMALE; GINGIVITIS; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; FELODIPINE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYPHARMACY; RAMIPRIL; TETRAZOLES; TIME FACTORS; VALINE; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; TREATMENT OUTCOME;

EID: 57949106203     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020802488855     Document Type: Article

References (35)

1. Wolf-Maier, K., Cooper, R. S., Kramer, H., Banegas, J. R., Giampaoli, S. Joffres, M. R. et al. (2004) Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension, 43, pp. 10-17.
2. Ong, K. L., Cheung, B. M. Y., Man, Y. B. and Lam, K. S. L. (2007) Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension, 49, pp. 69-75.
3. Hansson, L., Lloyd, A., Anderson, P. and Kopp, Z. (2002) Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press, 11, pp. 35-45.
4. Ogedegbe, G. (2008) Barriers to optimal hypertension control. J Clin Hypertens (Greenwich), 10, pp. 644-646.
5. Rose, A. J., Berlowitz, D. R., Orner, M. B. and Kressin, N. R. (2007) Understanding uncontrolled hypertension: Is it the patient or the provider?. J Clin Hypertens (Greenwich), 9, pp. 937-943.
6. Flack, J. M. (2007) Epidemiology and unmet needs in hypertension. J Manag Care Pharm, 13:8, pp. 2-8.
7. Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, pp. 1903-1913.
8. Zanchetti, A., Hansson, L., Menard, J., Leonetti, G., Rahn, K. H., Warnold, I. for the HOT Study Group et al. (2001) Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. J Hypertens, 19, pp. 819-825.
9. Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L. and for the VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet, 363, pp. 2022-2031.
10. Staessen, J. A., Thijisq, L., Fagard, R., Celis, H., Birkenhager, W. H., Bulpitt, C. J. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators et al. (2004) Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens, 22, pp. 847-857.
11. Weber, M. A., Julius, S., Kjeldsen, S. E., Brunner, H. R., Ekman, S. Hansson, L. et al. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet, 363, pp. 2049-2051.
12. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A. Izzo Jr, J. L. et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, pp. 1206-1252.
13. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) (2007) 2007 Guidelines for the management of arterial hypertension. J Hypertens, 25, pp. 1105-1187.
14. Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlof, B., Elmfeldt, D., Julius, S. for the HOT Study Group et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351, pp. 1755-1762.
15. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B. for the Collaborative Study Group et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345, pp. 851-860.
16. Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H. for the ALLHAT Collaborative Research Group et al. (2002) Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich), 4, pp. 393-404.
17. Dahlof, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M. for the ASCOT investigators et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowing Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet, 366, pp. 895-906.
18. Sica, D. A. (2002) Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs, 62, pp. 443-462.
19. Law, M. R., Wald, N. J., Morris, J. K. and Jordan, R. E. (2003) Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ, 326, pp. 1427-1434.
20. Jamerson, K. A., Nwose, O., Jean-Louis, L., Schofield, L., Purkayastha, D. and Baron, M. (2004) Initial angiotensin-converting enzyme inhibitor/ calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens, 17, pp. 495-501.
21. Weber, M. A., Ruilope, L., Giles, T. D. and Izzo Jr, J. L. (2007) First-step use of fixed-dose combination treatment in stage 2 hypertensive patients: Has the time come?. J Clin Hypertens (Greenwich), 9, pp. 276-284.
22. Elliott, W. J. (2002) Is fixed combination therapy appropriate for initial hypertension treatment?. Curr Hypertens Rep, 4, pp. 278-285.
23. Osterberg, L. and Blaschke, T. (2005) Drug therapy: Adherence to medication. N Engl J Med, 353, pp. 487-497.
24. Gerbino, P. P. and Shoheiber, O. (2007) Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm, 64, pp. 1279-1283.
25. Weir, M. R. (2007) Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. J Hum Hypertens Published online 28 June
26. Jamerson, K. A. and on behalf of the ACCOMPLISH investigators Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension.
27. Poldermans, D., Glazes, R., Kargiannis, S., Wernsing, M., Kaczor, J. Chiang, Y. T. et al. (2007) Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther, 29, pp. 279-289.
28. Blacher, J., Staessen, J. A., Girerd, X., Gasowski, J., Thijs, L. Liu, L. et al. (2000) Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med, 160, pp. 1085-1089.
29. Fogari, R., Zoppi, A., Derosa, G., Mugellini, A., Lazzari, P. Rinaldi, A. et al. (2007) Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens, 21, pp. 220-224.
30. Messerli, F. H. (2003) Evolution of calcium antagonists: Past, present, and future. Clin Cardiol, 26, pp. II12-II16.
31. Smith, T. R., Philipp, T., Vaisse, B., Bakris, G. L., Wernsing, M., Yen, J. and Glazer, R. (2007) Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: Subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich), 9, pp. 355-364.
32. Weber, M. A., Goldberg, A. I., Faison, E. P., Lipschutz, K., Shapiro, D. A. Nelson, E. B. et al. (1994) Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. Clin Pharmacol Ther, 55, pp. 346-352.
33. (2006) Delmuno® 5/5 mg [Summary of product characteristics].
34. Scholze, J., Bauer, B. and Massaro, J. (1999) Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. Clin Exp Hypertens, 21, pp. 1447-1462.
35. Bramley, T. J., Gerbino, T. T., Nightengale, B. S. and Frech-Tames, F. (2006) Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm, 12, pp. 239-245.